Marseille, France Monday, July 21, 2025, 12:00 Hrs [IST] ...

ImCheck Therapeutics just raised $103 million to treat multiple forms of cancer. The company is working on one of the fastest-growing ideas in cancer research: gamma-delta T cells.

ImCheck Therapeutics’ contribution is a type of drug that could bring advantages over the first generation of cancer immunotherapies. Now the biotech has €96M that will help continue clinical ...

MARSEILLE, France, Aug. 1, 2019 /PRNewswire/ -- ImCheck Therapeutics, a biotech company on the cutting edge of the next wave of immunotherapies against cancer and autoimmune diseases, announced ...

ImCheck Therapeutics raises €20 Million and appoints its CEO Emerging leader in immuno-oncology accelerates its development programs and prepares for entry into the clinic Marseille, France, May ...

ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies positioned at the crossroads of two high-potential immunological fields: ...

Marseille, France, April 23, 2025 10:00 a.m. ET / 4:00 p.m. CET– ImCheck Therapeutics announced today an oral presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual ...

With all that on the to-do list, ImCheck Therapeutics has refueled with a 96 million euro ($101 million) funding round that featured existing investors Pfizer, Gimv and more.

ImCheck Therapeutics Appoints Dr. Loui Madakamutil, Noted Expert in Immunology and Autoimmune Diseases, as Chief Scientific Officer Marseille, France, April 15, 2021 – ImCheck Therapeutics today ...

Imcheck Therapeutics SAS’s gamma-delta T-cell activating antibody has become a poster child for the French government’s plan to reduce dependence on imports of biopharmaceuticals by directly ...

ImCheck’s ICT01 Receives FDA Orphan Drug Designation Clinical data showing unprecedented remission rates in newly diagnosed ...